公开(公告)号：US20230340471A1

公开(公告)日：2023-10-26

申请号：US17963631

申请日：2022-10-11

Applicant: Ospedale San Raffaele S.R.L. ,  Fondazione Telethon

Inventor： Luigi Naldini ,  Angelo Leone Lombardo ,  Angelo Amabile ,  Alessandro Migliara

IPC: C12N15/113 ,  C12N9/10 ,  C07K14/47 ,  A61K38/45 ,  A61K48/00 ,  A61K35/12 ,  A61K38/17 ,  C12N9/22

CPC classification number: C12N15/113 ,  C12N9/1007 ,  C07K14/4703 ,  C12Y201/01037 ,  C12Y201/01043 ,  A61K38/45 ,  A61K48/005 ,  A61K35/12 ,  A61K38/1709 ,  C12N9/22 ,  C07K2319/80 ,  C12N2740/16043 ,  C12N2310/20 ,  A61K38/00

Abstract: A product comprising two or more artificial transcription repressors (ATRs), or polynucleotides encoding therefor, selected from groups (a), (b), (c) or (d): (a) an ATR comprising a DNA-binding domain operably linked to a KRAB domain or homologue thereof; (b) an ATR comprising a DNA-binding domain operably linked to a DNMT3A, DNMT3B or DNMT1 domain or homologue thereof; (c) an ATR comprising a DNA-binding domain operably linked to a DNMT3L domain or homologue thereof; and (d) an ATR comprising a DNA-binding domain operably linked to a SETDB1 domain or homologue thereof, wherein at least two of the ATRs are selected from different groups (a), (b), (c) or (d).

公开(公告)号：US20230174978A1

公开(公告)日：2023-06-08

申请号：US17698912

申请日：2022-03-18

Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.

Inventor： David Arthur Berry ,  Rahul Karnik ,  Laura Gabriela Lande

IPC: C12N15/113 ,  C12N9/22 ,  C12N15/63 ,  C12N15/85 ,  C12N15/87 ,  C12N15/90 ,  C12N9/00 ,  C12N9/10 ,  C12N9/80 ,  A61K35/12

CPC classification number: C12N15/113 ,  A61K35/12 ,  C12N9/00 ,  C12N9/22 ,  C12N9/80 ,  C12N9/1007 ,  C12N15/63 ,  C12N15/85 ,  C12N15/87 ,  C12N15/90 ,  C12N15/907 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y305/01098 ,  A01K2217/056 ,  A01K2227/706 ,  A01K2267/0318 ,  C07K2319/00 ,  C07K2319/85 ,  C12N2310/14 ,  C12N2310/20

Abstract: The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

公开(公告)号：US09683995B2

公开(公告)日：2017-06-20

申请号：US14701810

申请日：2015-05-01

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Leonard I. Zon ,  Craig Ceol ,  Yariv J. Houvras

IPC: G01N33/574 ,  A61K39/395 ,  C07K16/40 ,  C12N15/11 ,  C12Q1/68 ,  C12N15/113

CPC classification number: G01N33/5743 ,  A61K39/39558 ,  C07K16/40 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/574 ,  G01N2333/91011 ,  G01N2333/91017

Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.

公开(公告)号：US20170022504A1

公开(公告)日：2017-01-26

申请号：US15171860

申请日：2016-06-02

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/113 ,  A61K9/127 ,  A61K31/713

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸以及用于靶向lncRNA的方法和组合物。

公开(公告)号：US20160068834A1

公开(公告)日：2016-03-10

申请号：US14772143

申请日：2014-03-13

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Loren D. Walensky

IPC: C12N9/96 ,  C12N9/10

CPC classification number: C12N9/96 ,  A61K38/00 ,  C07K14/47 ,  C12N9/1007 ,  C12Y201/01043

Abstract: Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.

Abstract translation: 本文提供含有与味精同系物2（EZH2），组蛋白赖氨酸N-甲基转移酶增强子相关的稳定治疗肽的多肽。 还提供了含有这些多肽的组合物和在治疗癌症中使用这些肽的方法，其包括向受试者施用一种多肽。

公开(公告)号：US20160053258A1

公开(公告)日：2016-02-25

申请号：US14778600

申请日：2014-11-03

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Daeyoup Lee ,  Seung-Kyoon Kim ,  Hosuk Lee

IPC: C12N15/113 ,  C12N15/115 ,  C07K16/18

CPC classification number: C12N15/113 ,  C07K16/18 ,  C07K2317/76 ,  C12N5/0606 ,  C12N15/1137 ,  C12N15/115 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2320/30 ,  C12Y201/01043

Abstract: Provided is a composition for controlling pluripotency of stem cells including an LIN28A methylation inhibitor and a screening method of the LIN28A methylation inhibitor, and more particularly, a composition for controlling pluripotency of stem cells including an inhibitor controlling methylation of 135th lysine of LIN28A that is methylated by SET7/9, or a composition for treating cancer, and a screening method of the inhibitor, wherein the screening method includes (a) contacting a candidate material with a cell, the cell having a gene introduced thereinto; (b) measuring a methylation level of the 135th lysine of the LIN28A; and (c) selecting an inhibitor controlling methylation of the 135th lysine of the LIN28A. That is, the present invention relates to a composition for controlling pluripotency of embryonic stem cells, or an anti-cancer composition, and a screening method of the inhibitor. The method of the present invention is possible to screen materials capable of controlling pluripotency of embryonic stem cells or materials having anti-cancer activity, and the materials screened by the method of the present invention may control pluripotency of embryonic stem cells and inhibit growth of cancer cells, which is effective for disorders of stem cell differentiation or preparation of cancer therapeutic agents.

Abstract translation: 提供了用于控制包括LIN28A甲基化抑制剂和LIN28A甲基化抑制剂的筛选方法的干细胞的多能性的组合物，更具体地，涉及用于控制干细胞多能性的组合物，其包括控制甲基化的LIN28A的第135位赖氨酸甲基化的抑制剂 通过SET7 / 9或用于治疗癌症的组合物和抑制剂的筛选方法，其中所述筛选方法包括（a）使候选物质与细胞接触，所述细胞具有引入其中的基因; （b）测量LIN28A的第135位赖氨酸的甲基化水平; 和（c）选择控制LIN28A的第135位赖氨酸甲基化的抑制剂。 也就是说，本发明涉及用于控制胚胎干细胞的多能性的组合物，或抗癌组合物，以及抑制剂的筛选方法。 本发明的方法可以筛选能够控制胚胎干细胞的多能性或具有抗癌活性的材料，并且通过本发明的方法筛选的材料可以控制胚胎干细胞的多能性并抑制癌症的生长 细胞，其对于干细胞分化障碍或癌症治疗剂的制备是有效的。

公开(公告)号：US09045801B2

公开(公告)日：2015-06-02

申请号：US13945439

申请日：2013-07-18

Applicant: British Columbia Cancer Agency Branch

Inventor： Ryan D. Morin ,  Marco A. Marra ,  Randy D. Gascoyne ,  Joseph M. Connors

IPC: C12Q1/68 ,  C12N9/10 ,  C07K16/40 ,  G01N33/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C07K16/40 ,  C12N9/1007 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N33/6872 ,  G01N2800/52

Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.

Abstract translation: 本公开提供了将受试者鉴定为具有B细胞非霍奇金淋巴瘤（NHL）的方法，例如测试来自受试者的样品用于一种或多种生物标志物中的突变。 还描述了用于分类或监测具有或怀疑具有B细胞非霍奇金淋巴瘤的受试者的方法，包括测试样品中一种或多种生物标志物中的突变。

公开(公告)号：US20150150156A1

公开(公告)日：2015-05-28

申请号：US14371986

申请日：2013-01-11

Applicant: The Regents of the University of California

Inventor： Steve E. Jacobsen ,  Elena Caro

IPC: C12N15/82 ,  C12N9/10

CPC classification number: C12N15/8218 ,  C07K14/415 ,  C12N9/1007 ,  C12N15/8216 ,  C12N15/827 ,  C12Y201/01043

Abstract: The present disclosure relates to recombinant methyltransferases that epigenetically silence gene expression and to methods of using such proteins for reducing the expression of genes in plants.

Abstract translation: 本公开涉及表观遗传沉默基因表达的重组甲基转移酶以及使用这些蛋白质降低植物中基因表达的方法。

公开(公告)号：US08715678B2

公开(公告)日：2014-05-06

申请号：US13415474

申请日：2012-03-08

Applicant: Michael S. Cosgrove ,  Anamika Patel

Inventor： Michael S. Cosgrove ,  Anamika Patel

IPC: A01N61/00

CPC classification number: C12N9/99 ,  C07K14/4702 ,  C12Y201/01043

Abstract: Disclosed in this specification is a method for inhibiting the formation of vertebrate SET1 family core complexes. A guanidinium-containing molecule is used to competitively inhibit the binding of the N-SET region of a SET1 protein to WDR5, thus inhibiting the formation of the SET1 family core complex. The guanidinium-containing molecule may be, for example, an arginine-containing peptide.

Abstract translation: 在本说明书中公开的是抑制脊椎动物SET1家族核心复合物形成的方法。 使用含胍基分子竞争性地抑制SET1蛋白的N-SET区与WDR5的结合，从而抑制SET1家族核心复合物的形成。 含有胍基的分子可以是例如含精氨酸的肽。

公开(公告)号：US20140094387A1

公开(公告)日：2014-04-03

申请号：US14123403

申请日：2012-05-31

Applicant: Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

Inventor： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

IPC: C12Q1/68 ,  C12Q1/48

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/48 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57411 ,  G01N33/57423 ,  G01N33/57434 ,  G01N2500/04

Abstract: Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer.

Abstract translation: 本文描述了用于检测或诊断癌症或确定发展癌症，特别是肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤的倾向的客观方法。 在一个实施方案中，诊断方法包括确定SUV39H2基因的表达水平。 本发明还提供了筛选用于治疗和/或预防SUV39H2相关癌症（例如肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤）的候选物质的方法。 本发明进一步提供抑制细胞生长，从而治疗或减轻SUV39H2相关癌症症状的方法。 本发明还具有针对SUV39H2基因的双链分子及其编码载体以及含有这些组分的组合物及其与治疗和预防SUV39H2相关癌症有关的用途。